Studies Examined Medicare Bronchiectasis Costs
New research detailed health care utilization and national prevalence rates for non-cystic fibrosis bronchiectasis.
Updated on Oct. 14, 2026 in Asthma
Live Poll
Do you trust the federal government to effectively manage rising healthcare costs for Medicare beneficiaries?
Two recent studies identified high health care spending and utilization among Medicare beneficiaries with non-cystic fibrosis bronchiectasis between 2017 and 2022. The 2023 national prevalence of this condition reached 1004 per 100,000 person-years among beneficiaries.
Why it matters
Understanding the clinical and financial burden of this condition provides critical data on the healthcare needs of elderly patients. These findings highlight the significant hospital resources utilized by those managing this chronic lung disease.
Beneficiaries with the condition had a mean monthly fee-for-service spend of $8998, with 66.2% of that group experiencing inpatient hospitalization. The study cohort had a mean age of 75.9 years and was 61.0% female.
The players
Medicare
This is the federal health insurance program that provided the enrollment and claims data used for the analysis of bronchiectasis prevalence and costs.
CHEST
This professional organization is hosting the 2026 Annual Meeting where these medical study findings will be officially presented.
The details
Researchers analyzed 100% of US Medicare enrollment and claims data from 2016 through 2023 to define non-cystic fibrosis bronchiectasis cases. The study identified 535,038 beneficiaries who met the diagnostic criteria in 2023, where 64.1% of that population was female.
Timeline
Data collection for the study covered the period from January 1, 2016, to December 31, 2023.
Incident cases were tracked during the period between 2017 and 2022.
The prevalence calculation was based on data from 2023.
Findings are scheduled for presentation at the CHEST 2026 Annual Meeting from October 18-21, 2026.
The Big Picture
These findings will be presented at the CHEST Annual Meeting, a major forum for sharing clinical developments in pulmonology. The research provides updated data that bridges gaps in understanding the current impact of non-cystic fibrosis bronchiectasis on the aging population.
Patients and caregivers should be aware that this condition involves high healthcare utilization, often requiring inpatient hospital care. Understanding these cost and utilization metrics may assist in long-term treatment planning and insurance discussions for Medicare beneficiaries.
The takeaway
This analysis illustrates the significant financial and hospital resource demands associated with bronchiectasis in elderly patients. Medicare beneficiaries managing this condition should prioritize coordinated care to address the high rates of hospitalization observed in the data.
What happens next
The findings are scheduled to be presented at the CHEST 2026 Annual Meeting in Phoenix, Arizona, from October 18-21, 2026.
Further reading
For additional context on chronic lung conditions, visit the Asthma section.
Live Poll
Do you trust the federal government to effectively manage rising healthcare costs for Medicare beneficiaries?
